Subgroup baseline characteristics analyses noted that an association between SGLT2 inhibitors and a lower risk of gout was present in significantly more younger (age <65 years) than older (age ≥65 years) age groups (P = .01 for interaction). This evidence concerns the gene SLC5A2 and gout.